{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:07:50Z","timestamp":1793351270600,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019708","name":"UroGen Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.euf.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T14:06:16Z","timestamp":1632751576000},"page":"1117-1120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non\u2013muscle-invasive bladder cancer: Pro"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-146X","authenticated-orcid":false,"given":"Mathieu","family":"Roumigui\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2021.07.018_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2021.07.018_bib0010","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.07.018_bib0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"2","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2021.07.018_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2021.07.018_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2021.07.018_bib0030","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bju.14423","article-title":"Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes","volume":"122","author":"Pandey","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.07.018_bib0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2021.07.018_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.07.022","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euf.2021.07.018_bib0045","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"38","author":"Black","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2021.07.018_bib0050","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus Calmette-Guerin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.07.018_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.07.018_bib0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/cancers13030377","article-title":"Long-term experience with radiofrequency-induced hyperthermia combined with intravesical chemotherapy for non-muscle invasive bladder cancer","volume":"13","author":"Brummelhuis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2021.07.018_bib0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2021.07.018_bib0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/BLC-180187","article-title":"Intravesical radiofrequency-induced chemohyperthermia for carcinoma in situ of the urinary bladder: a retrospective multicentre study","volume":"4","author":"van Valenberg","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2021.07.018_bib0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2021.07.018_bib0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2021.39.6_suppl.510","article-title":"Phase II\/III clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients","volume":"39","author":"Chamie","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.euf.2021.07.018_bib0085","first-page":"e72","article-title":"Phase 3 results of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921002340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921002340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:53:01Z","timestamp":1762498381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456921002340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2405456921002340"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2021.07.018","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non\u2013muscle-invasive bladder cancer: Pro","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}